IDH1 and glioma: Overall, regardless of the presence of 1p19q codel, both studies demonstrated that DAC and AZA induce durable therapeutic effects in patient-derived IDH1-mutant gliomas without any signs of tumor re-growth despite termination of administration [83,102].